• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » WHO urges governments to invest $34B for neglected tropical diseases

WHO urges governments to invest $34B for neglected tropical diseases

February 20, 2015
CenterWatch Staff

The World Health Organization (WHO) has released a report urging countries to scale up their investment in tackling 17 neglected tropical diseases in order to improve the health and well-being of more than 1.5 billion people. This investment would represent as little as 0.1% of current domestic expenditure on health in affected low- and middle-income countries for the period 2015-2030.

Neglected tropical diseases cause blindness, disfigurement, permanent disability and death, particularly among the poor. WHO’s new report, Investing to overcome the impact of neglected tropical diseases, outlines an investment case and essential package of interventions for these diseases.

“Increased investments by national governments can alleviate human misery, distribute economic gains more evenly and free masses of people long trapped in poverty,” said Dr. Margaret Chan, WHO director-general.

An annual investment of $2.9 billion until 2020 (including vector control), is required to reach targets set in 2012 in the WHO Roadmap for 2015-2020. For the following 10 years (2021-2030), investment requirements will drop to $1.6 billion per year. Annual investments will continue to decrease as diseases are reduced or eliminated. This adds up to a total investment of $34 billion (over 16 years) and excludes cost of donated medicines and other in-kind contributions.

The report highlights progress made in recent years, largely attributed to a scale-up of control interventions in reaching the poorest. For example, in 2012 alone, more than 800 million people were treated for at least one neglected tropical disease. In 2014 there were just 126 cases reported of Dracunculiasis (guinea-worm disease), compared to almost 1800 in 2010 and 3.5 million in the mid-1980s. Eradication of this disease is achievable with continued effort and investment.

By 2017, the number of people receiving preventive treatment for at least one of the diseases should reach 1.5 billion. As diseases are reduced or eliminated, the number of people needing and receiving treatment will obviously fall. Early detection of some neglected tropical diseases will allow more children to continue school and adults to work while reducing the costs associated with treating more advanced forms of these diseases.

Moving toward universal health coverage will ensure that all people have access to preventive and curative health services for neglected tropical diseases without the risk of financial hardship when paying for them.

In the face of climate change, countries need to strengthen their ability to anticipate and meet new challenges in terms of vector ecology and management. Diseases spread by insects are on the move because of rapid and unplanned urbanization, population movement and environmental change. Dengue is one of them: it now is present in more than 150 countries.

“Some of the neglected tropical diseases are no longer strictly tropical,” said Dr. Dirk Engels, director of the WHO Control of Neglected Tropical Diseases Department. “The potential for spread provides yet another strong argument for making the needed investments—while ramping up R&D efforts—to bring all these diseases under control and eliminate as many of them as rapidly as possible.”

Many countries have recognized the importance and cost effectiveness of investing in preventing and treating neglected tropical diseases. More than 70 countries already are implementing or ready to kick off national plans for accelerated control.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing